Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin

Valerie Edmond^{1,2}, Elodie Moysan^{1,2},
Saadi Khochbin^{2,3}, Patrick Matthias⁴,
Christian Brambilla^{1,2}, Elisabeth Brambilla^{1,2},
Sylvie Gazzeri^{1,2} and Beatrice Eymin^{1,2,*}

¹INSERM, U823, Equipe 2 Bases Moléculaires de la Progression des Cancers du Poumon, Institut Albert Bonniot, Grenoble, France,

²Université Joseph Fourier, Institut Albert Bonniot, Grenoble, France,

³INSERM, U823, Equipe 6, Epigénétique et Signalisation cellulaire, Grenoble, France and ⁴Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland

SRSF2 is a serine/arginine-rich protein belonging to the family of SR proteins that are crucial regulators of constitutive and alternative pre-mRNA splicing. Although it is well known that phosphorylation inside RS domain controls activity of SR proteins, other post-translational modifications regulating SRSF2 functions have not been described to date. In this study, we provide the first evidence that the acetyltransferase Tip60 acetylates SRSF2 on its lysine 52 residue inside the RNA recognition motif, and promotes its proteasomal degradation. We also demonstrate that the deacetylase HDAC6 counters this acetylation and acts as a positive regulator of SRSF2 protein level. In addition, we show that Tip60 downregulates SRSF2 phosphorylation by inhibiting the nuclear translocation of both SRPK1 and SRPK2 kinases. Finally, we demonstrate that this acetylation/phosphorylation signalling network controls SRSF2 accumulation as well as *caspase-8* pre-mRNA splicing in response to cisplatin and determines whether cells undergo apoptosis or G₂/M cell cycle arrest. Taken together, these results unravel lysine acetylation as a crucial post-translational modification regulating SRSF2 protein level and activity in response to genotoxic stress.

The EMBO Journal (2011) 30, 510–523. doi:10.1038/emboj.2010.333; Published online 14 December 2010

Subject Categories: RNA

Keywords: acetylation; phosphorylation; SRPK; SRSF2; Tip60

Introduction

Pre-mRNA splicing consists of a highly regulated cascade of events that are critical for gene expression in higher eukaryotic cells. This process has emerged as an important mechanism of genetic diversity, as about 92–94% of human genes undergo alternative splicing, leading to the synthesis of various protein isoforms with different biological properties (Wang *et al*, 2008). SRSF2 belongs to the serine/arginine-rich

(SR) protein family, one of the most important class of splicing regulators that has a prominent role in splice-site selection, in multiples steps of spliceosome assembly as well as in both constitutive and alternative splicing (Long and Caceres, 2009). All members of the SR protein family share a modular organization and contain one or two N-terminal RNA recognition motifs (RRMs) that interact with the pre-mRNA, and influence substrate specificity (Liu *et al*, 1998), as well as a C-terminal SR sequence known as the RS domain that functions as a protein–protein interaction module (Wu and Maniatis, 1993). Activity of SR proteins is highly regulated by extensive and reversible phosphorylation of serine residues inside RS domain. These phosphorylations modulate protein–protein interactions within the spliceosome and can influence RNA-binding specificity, splicing activity and sub-cellular localization. To date, numerous kinases phosphorylating SR proteins have been identified. They include the SRPK and CLK/STY family kinases that are highly specific for RS domain-containing splicing factors, the DNA topoisomerase I and AKT (Stamm, 2008). However, data addressing the cellular signals that control phosphorylation of SR proteins remain scarce, as well as the specific kinases involved in these effects.

Chromatin biology and pre-mRNA splicing have been considered for a long time as two independent fields. However, recently, chromatin structure has been shown to affect both constitutive and alternative splicing, either through the recruitment of splicing factors (Sims *et al*, 2007) or through the modulation of RNA polymerase II elongation rate (Batsche *et al*, 2006). In addition, two studies have demonstrated that DNA sequences associated with nucleosomes are preferentially located in exons (Schwartz *et al*, 2009; Tilgner *et al*, 2009), providing a general concept for how the architecture of genome packaging could influence pre-mRNA splicing. Chromatin structure is highly controlled by post-translational modifications of histone protein tails including phosphorylation or acetylation. These modifications are catalysed by chromatin-modifying enzymes that add or remove specific groups in a reversible way. It was recently reported that two SR proteins, namely SRSF3 and SRSF1, bind histone H3 tail to control cell cycle progression (Loomis *et al*, 2009). These data provide the first evidence that SR proteins associate with chromatin, and suggest that they could also be directly targeted by components of chromatin-remodeling complexes. Lysine acetylation is highly regulated through the opposite actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) enzymes. Besides histones, an increasing number of cellular proteins are also subjected to lysine acetylation (Yang and Seto, 2008). Recently, a high-resolution mass spectrometry analysis revealed that a large number of acetylation sites are present on proteins implicated in splicing, including SR proteins, and identified the RRM as a major domain for acetylation (Choudhary *et al*, 2009). These data support the idea that lysine acetylation could regulate the function of SR proteins.

*Corresponding author. INSERM U823 Equipe 2, Institut Albert Bonniot, BP170, 38042 Grenoble Cedex 09, France. Tel.: +33 47 654 9476; Fax: +33 47 654 9413; E-mail: Beatrice.Eymin@ujf-grenoble.fr

Received: 18 May 2010; accepted: 17 November 2010; published online: 14 December 2010

In this study, we demonstrate for the first time that an acetylation/phosphorylation network controls the turnover and activity of the splicing factor SRSF2 in response to genotoxic stress. Therefore, besides phosphorylation, lysine acetylation also appears as a crucial post-translational modification of SR proteins.

Results

SRSF2, but not SRSF1, is acetylated by the HAT Tip60

To test whether SRSF2 could be acetylated, we first transfected SAOS2 cells with an expression vector encoding HA-tagged SRSF2 protein and used anti-HA antibody to immunoprecipitate SRSF2, the acetylated status of which was analysed by western blotting using an anti-acetyl-lysine antibody. As shown in Figure 1A, an acetylated form of SRSF2 was detected in these conditions. To go further, immunoprecipitation with anti-acetyl-lysine (Figure 1B, left panel) or anti-SRSF2 (Figure 1B, right panel) antibody was performed in nuclear-enriched extracts from H69 cells that express high levels of SRSF2. Again, an acetylated form of SRSF2 was detected by western blotting using an anti-SRSF2 or an anti-acetyl-lysine antibody, respectively. Together, these data provide the first evidence that SRSF2 is subjected to acetylation. During the course of this study, we demonstrated that the Tip60 acetyltransferase controls acetylation of non-histone proteins in our cellular models (Leduc *et al*, 2006; Van Den Broeck, unpublished results), and we postulated that SRSF2 could be a new Tip60 target. To test this hypothesis, an '*in vitro*' acetyltransferase assay was set up in which various truncated GST-SRSF2 fusion proteins were used as putative substrates for the Tip60 acetyltransferase (His-Tip60^{212–513}) in the presence of [¹⁴C]acetyl-CoA (Figure 1C). Of note, truncated fragments of SRSF2 were used in this assay, as full-length recombinant SRSF2 protein cannot be produced in bacteria. As detected by autoradiography (Figure 1D, upper panel), recombinant Tip60 was able to efficiently acetylate SRSF2 on its first 60 amino acids (1–60) encompassing the RRM. This effect was specific of Tip60 as another acetyltransferase, namely GCN5, was unable to acetylate the GST-SRSF2(1–60) fragment (Figure 1D, upper panel). No signal was detected with the GST-SRSF2(60–115) truncated fragment while a very faint signal, as compared with GST-SRSF2(1–60) fragment, was detected with the GST-SRSF2(115–221) truncated protein (Figure 1D, upper panel), suggesting that SRSF2 could also be acetylated by Tip60 inside its RS domain part. By contrast, when the recombinant SRSF1 protein was used as an '*in vitro*' substrate of either Tip60 or GCN5 acetyltransferase, acetylation could not be detected (Supplementary Figure 1). Although these results did not exclude the possibility that SRSF1 could also be subjected to acetylation (Choudhary *et al*, 2009), they indicate that SRSF1 is not a substrate of Tip60 *in vitro*. In order to confirm these results '*in vivo*', Tip60 was knocked down in H1299 cells and the acetylated status of endogenous SRSF2 was studied by immunoprecipitation using either an anti-acetyl-lysine (Figure 1E, upper panel) or an anti-SRSF2 (Figure 1E, lower panel) antibody followed by immunoblotting using an anti-SRSF2 or an anti-acetyl-lysine antibody, respectively. The data demonstrated that Tip60 neutralization significantly decreases SRSF2 acetylation in these cells. By contrast, and consistent with the *in vitro* experiments,

acetylation of SRSF1 could not be detected when the membrane loaded with the anti-acetyl-lysine immunoprecipitates was re-blotted with an anti-SRSF1 antibody (Figure 1E, upper panel). In addition, an interaction between both Tip60 and SRSF2 proteins was depicted in cells co-transfected with SRSF2- and Tip60-encoding plasmids (Supplementary Figure 2), indicating that both proteins exist in a complex within these cells. Overall, these results demonstrate that SRSF2 is a substrate of the acetyltransferase Tip60. SRSF2(1–60) N-terminal part contains three lysine (K) residues (K17, K36 and K52; Figure 1F, upper panel). To map the acetylation site(s) targeted by Tip60 on SRSF2 inside its RRM domain, we produced recombinant mutated GST-SRSF2(1–60) fusion proteins in which each lysine was substituted by an arginine (R), a non-acetylatable residue. Analysis of the K52R and K17R point mutants indicated that K52 was a prime-candidate site for Tip60-mediated acetylation as autoradiographic signal was dramatically lost when K52 residue was mutated into arginine (Figure 1F, lower panel). Of note, we were not able to produce the GST-SRSF2(1–60) K36 point mutant in bacterial system, so we cannot exclude the possibility that K36 could be acetylated. Taken together, these results demonstrate that Tip60 acetylates SRSF2 on its K52 residue.

Acetylation by Tip60 controls SRSF2 protein turnover

To investigate the biological consequences of Tip60-mediated SRSF2 acetylation, we knocked down Tip60 expression by using two distinct siRNA in various carcinoma cell lines and monitored the expression level of SRSF2. Immunoblotting experiments reproducibly demonstrated that SRSF2 protein level significantly increased when Tip60 was neutralized as compared with control cells (Figure 2A and Supplementary Figure 3A). This effect was specific of SRSF2 as SRSF1 protein amount was apparently not affected. This effect also mainly occurred at a post-transcriptional level as SRSF2 mRNA did not reproducibly increase under these conditions (Figure 2A and Supplementary Figure 3B). To confirm these results, rescue experiments were performed in which either the wild-type Tip60 or a mutant Tip60 with a defective HAT activity (Tip60^{G380}) was overexpressed in Tip60 knockout cells. As shown in Figure 2B, restoration of Tip60 expression in Tip60-deficient cells prevented SRSF2 protein accumulation while the mutant Tip60^{G380} did not. Moreover, and consistent with Tip60 being a negative regulator of SRSF2, SRSF2 protein level decreased when cells were co-transfected with Tip60-encoding plasmid (Figure 2C). Interestingly, treating cells with the proteasomal inhibitor MG132 prevented SRSF2 downregulation in that case, thereby indicating that SRSF2 could be subjected to a Tip60-mediated proteasomal degradation. By contrast, co-transfection with the mutant Tip60^{G380}-encoding plasmid had no significant effect on exogenous SRSF2 protein level (Figure 2C). Similar results were obtained when the effect of Tip60 or Tip60^{G380} was assessed on endogenous SRSF2 protein level (Figure 2D). Taken together, these data support the notion that Tip60-mediated SRSF2 acetylation controls SRSF2 turnover. To assess the role of K52 in this setting, we generated an expression vector encoding an HA-tagged SRSF2(K52R) mutant protein harbouring a K52R substitution, thereby mimicking a non-Tip60-acetylatable form of SRSF2. In co-transfection experiments, Tip60 as well as Tip60^{G380} were unable to

Figure 1 SRSF2 is acetylated on its lysine 52 (K52) residue by Tip60. **(A)** SAOS2 cells were transfected for 48 h with a HA-tagged SRSF2 expression vector. Whole-cellular extracts were subjected to immunoprecipitation (IP) with either anti-HA antibody or irrelevant immunoglobulin (IgG) as a negative control, followed by immunoblotting with anti-acetyl-lysine (Ac-K) or anti-HA antibody. **(B)** Endogenous acetylated SRSF2 protein was detected from H69 nuclear-enriched extract after immunoprecipitation of acetylated proteins with an anti-Ac-K (left panel) or anti-SRSF2 (right panel) antibody and immunodetection using anti-SRSF2 or anti-Ac-K antibody, respectively. **(C)** Representation of recombinant truncated GST-SRSF2 fusion proteins and recombinant His-tagged Tip60²¹²⁻⁵¹³ and GCN5 acetyltransferases. **(D)** Purified GST-SRSF2 fusion proteins were incubated with recombinant His-tagged Tip60²¹²⁻⁵¹³ or hGCN5 in the presence of [¹⁴C]acetyl-CoA. Acetylation was revealed after autoradiography (upper panel). Equivalent amounts of various recombinant proteins were assessed by Coomassie staining (lower panel). **(E)** H1299 cells were transfected for 48 h with either *mismatch* or *Tip60* siRNAs. Total cellular extracts were subjected to immunoprecipitation with an anti-Ac-K (upper panel) or an anti-SRSF2 (middle panel) antibody followed by immunoblotting with anti-SRSF2, anti-SRSF1 or anti-Ac-K antibody as indicated. Neutralization of Tip60 was controlled by quantitative RT-PCR (lower panel). **(F)** GST-SRSF2 (1-60) wild-type (WT) or point mutants (K17R; K52R) recombinant proteins were incubated with [¹⁴C]acetyl-CoA in the presence (+) or absence (–) of recombinant His-tagged Tip60²¹²⁻⁵¹³. Analysis of SRSF2 acetylation was performed as in **D**. K17R and K52R: substitution of the indicated lysine by arginine (lower panel). A full-colour version of this figure is available at *The EMBO Journal* Online.

modify the level of the SRSF2(K52R) mutant (Figure 2E). To confirm the role of the K52 residue on SRSF2 half-life, H1299 cells were transfected with plasmid encoding either

HA-tagged wild-type (WT) or mutant (K52R) SRSF2 protein and incubated with cycloheximide (CHX), a widely used inhibitor of translation. The amount of HA-SRSF2 WT or

HA-SRSF2 (K52R) protein was then analysed by immunoblotting. As depicted in Figure 2F, the mutant SRSF2(K52R) half-life was strongly enhanced as compared with that of wild-type SRSF2. When similar experiments were performed in HA-Tip60-transfected cells, Tip60 was found to reduce the half-life of HA-SRSF2 protein, while it did not affect that of the HA-SRSF2(K52R) mutant (Supplementary Figure 4). Overall, these results demonstrate that acetylation of SRSF2 by Tip60 negatively controls the expression level of the SRSF2 protein by a mechanism involving the proteasome pathway.

The deacetylase HDAC6 positively controls SRSF2 protein level

Lysine acetylation is finely regulated by the equilibrium between acetyltransferase and deacetylase activities. Among HDACs, HDAC6 is unique as it possesses intrinsic ubiquitin-linked functions, in addition to its deacetylase activity (Seigneurin-Berny *et al*, 2001; Boyault *et al*, 2006), and has been reported to protect ubiquitinated proteins from subsequent processing by the proteasome (Boyault *et al*, 2006, 2007b). Having demonstrated that acetylation controls SRSF2 protein turnover via a proteasome-dependent mechanism, we investigated the role of HDAC6. First, HA-tagged SRSF2 was expressed in the presence or absence of HDAC6. As shown in Figure 3A, overexpressing HDAC6 induced a strong accumulation of SRSF2 protein without affecting its mRNA level (Supplementary Figure 5A). Conversely, neutralizing HDAC6 by using siRNA significantly decreased SRSF2 protein expression, but not SRSF2 mRNA or SRSF1 protein level (Figure 3B and data not shown). Overall, these data indicated that HDAC6 positively controls SRSF2 expression level. In addition, both HDAC6 and SRSF2 proteins were found to co-immunoprecipitate (Supplementary Figure 5B). To investigate the role of K52 in this setting, we generated an anti-Ac-K52 SRSF2 antibody recognizing SRSF2 acetylated onto K52 (Supplementary Figure 6). Immunoprecipitation experiments of acetylated K52-SRSF2 were carried out in cells deprived of HDAC6 followed by immunoblotting directed against SRSF2. The results showed that knocking down HDAC6 induced the accumulation of an acetylated form of SRSF2 (Figure 3C, upper panel). Interestingly, HDAC6 was unable to stabilize the mutant SRSF2(K52R) as compared with the wild-type SRSF2 protein (Figure 3C, middle panel). In addition, the knockdown of HDAC6 in cells overexpressing either the SRSF2 or mutant SRSF2(K52R) construct severely decreased wild-type SRSF2 protein level while it had no effect on SRSF2(K52R) protein expression (Figure 3C, lower panel). Taken together, these results indicate that HDAC6 targets K52 to positively control SRSF2 protein expression. To extend these data, we took advantage of 3T3 cell lines, previously established from mouse embryo fibroblasts isolated from parental (WT) or HDAC6-deficient (KO) mice, in which wild-type HDAC6 was re-expressed (+ WT; Boyault *et al*, 2007b) and analysed the expression of murine SRSF2 by immunoblotting. As expected from the above data, SRSF2 protein level was significantly decreased in HDAC6^{-/-} 3T3 as compared with parental cells, and reintroduction of wild-type HDAC6 in knockout cells restored the basal level of SRSF2 protein (Figure 3D, upper panel). HDAC6 is a unique class II deacetylase which contains two catalytic domains, and a C-terminal zinc finger domain (ZnF-UBP) that binds

with high-affinity free ubiquitin as well as mono- and poly-ubiquitinated proteins (Boyault *et al*, 2007a). To characterize the functional domains of HDAC6 involved in SRSF2 regulation, we monitored the expression of SRSF2 in 3T3 cells derived from HDAC6-deficient mice re-expressing either the wild-type HDAC6 (+ WT), the HDAC6 mutant deprived of deacetylase activity (+ HD^m) or the HDAC6 mutant deprived of ubiquitin-binding function (+ Ub^m). The results showed that both mutants were unable to rescue the downregulation of SRSF2 on HDAC6 loss as compared with wild-type HDAC6 (Figure 3D, lower panel). In addition, HDAC6 was absolutely required for the accumulation of SRSF2 in 3T3 cells treated with MG132 (Figure 3E). This effect was dependent on both the catalytic activity and the ability of HDAC6 to bind ubiquitin. Overall, these results demonstrate that HDAC6 is a key factor of SRSF2 protein turnover and identify the crucial role of its catalytic and ubiquitin-binding domains in this setting. Finally, as the ratio between Tip60 and HDAC6 proteins could be a determinant of SRSF2 expression, we performed co-transfection experiments in which increasing amounts of HDAC6 were produced in the presence of high levels of Tip60. As shown in Figure 3F (upper panel), HDAC6 thoroughly reversed Tip60-mediated downregulation of SRSF2, even at a low level, indicating that HDAC6 activity outweighs the negative regulation of SRSF2 imposed by Tip60. By contrast, and consistent with K52 being a key residue in this setting, HDAC6 did not affect the expression level of SRSF2(K52R) in cells overexpressing Tip60 (Figure 3F, lower panel). As a whole, our data support a model in which HDAC6 has a key role in the maintenance of SRSF2 protein level by inhibiting Tip60-mediated acetylation and proteasomal degradation. These results are the first evidence that an acetylation/deacetylation switch controls SRSF2 protein turnover.

Tip60 inhibits SRSF2 phosphorylation by preventing SRPK1 and SRPK2 nuclear translocation

Numerous studies have now identified cross talks between lysine acetylation and others post-translational modifications, such as phosphorylation (Yang and Seto, 2008). As phosphorylation is a critical regulator of the activity of SR proteins, we then asked whether acetylation could affect the phosphorylation status of SRSF2. To explore this possibility, we used two different antibodies recognizing phosphorylated forms of SRSF2 (Figure 4A and Supplementary Figure 7) and we first analysed the phosphorylation level of SRSF2 in cells transfected with a plasmid encoding Tip60-HA, in the presence of MG132 to prevent SRSF2 proteasomal degradation. Overexpression of Tip60 significantly attenuated SRSF2 phosphorylation (Figure 4A). The effect of Tip60 required its HAT activity as SRSF2 phosphorylation was not affected by mutant Tip60^{G380}. To confirm these results, HA-tagged SRSF2 protein was overexpressed together with or without Tip60 in cells treated with MG132, and its phosphorylated status was assessed after immunoprecipitation with an anti-HA antibody followed by immunoblotting using the anti-phospho SRSF2 antibody. As shown in Figure 4B, Tip60 overexpression strongly decreased the phosphorylation of SRSF2. In addition, phospho-SRSF2 protein level was enhanced when Tip60 was neutralized by siRNA (Figure 4C). Altogether, these data indicate that Tip60 negatively controls SRSF2 phosphorylation and suggest a dialogue between acetylation and phos-

phorylation networks to control SRSF2 protein activity. Among the growing list of SR protein kinases, the SRPK family that includes SRPK1 and SRPK2 is well characterized. Interestingly, we provided evidence that downregulation of either SRPK1 or SRPK2 protein attenuated SRSF2 phosphorylation, whereas treatment with TG003, a pharmacological inhibitor of CLK/STY, another SR-phosphorylating kinase, had no effect (Supplementary Figure 8). Overall, these data indicate that both SRPK1 and SRPK2 kinases largely contribute to SRSF2 phosphorylation in our cellular models. Therefore, to test whether Tip60 could prevent SRSF2 phos-

phorylation by altering the expression level of SRPK(s), we performed immunoblotting experiments using whole-cell extracts of cells in which Tip60 expression was either upregulated or knocked down. As shown in Figure 4D and E (upper panels), overexpression or neutralization of Tip60 did not significantly modify the total amount of SRPK1 or SRPK2 protein. SRPK1 and SRPK2 kinases are proteins that shuttle between the cytoplasm and the nucleus (Ding *et al*, 2006). So, we next tested whether Tip60 could alter SRPK(s) subcellular distribution. To this purpose, cellular fractionation experiments were set up in cells transfected with either

Tip60-encoding plasmid or *Tip60* siRNA, and SRPK protein levels were analysed by immunoblotting in nuclear or cytoplasmic fractions. A significant decrease of nuclear SRPK(s) correlated with a decreased level of nuclear phosphorylated SRSF2 protein (P-SRSF2) protein was observed on *Tip60* overexpression as compared with control cells (Figure 4D, lower panel). By contrast, strong nuclear accumulation of SRPK(s) associated with P-SRSF2 increase was observed in cells knocked down for *Tip60* as compared with *mismatch* transfected cells (Figure 4E, lower panel). To confirm these results, immunofluorescence studies were set up. As shown in Figure 4F, the nuclear amount of both SRPK1 and SRPK2 proteins increased in cells deprived of *Tip60* as compared with *mismatch* transfected cells. Conversely, a slight but reproducible decrease of both SRPK1 and SRPK2 nuclear staining was observed in cells overexpressing *Tip60*, whereas this effect was not observed with the mutant *Tip60*^{G380} (Supplementary Figure 9). Altogether, these results indicate that *Tip60* negatively controls SRSF2 phosphorylation and the nuclear accumulation of SRPK kinases, by a mechanism requiring its HAT activity. Of note, HDAC6 neither affected SRSF2 phosphorylation status, nor modified SRPK(s) protein levels or subcellular localization in our cellular models (data not shown).

SRSF2 accumulates in a hypoacetylated/ phosphorylated form in response to cisplatin treatment

We finally attempted to characterize in which physiological context the signalling networks involving *Tip60*, HDAC6 and SRPK(s) proteins controlled SRSF2 protein status. We recently demonstrated that SRSF2 was upregulated and required for the apoptotic response induced by alkylating agents (Merdzhanova *et al*, 2008). In this study, we provided evidence that SRSF2 also accumulates following cisplatin treatment (Figure 5A, left panel). As quantitative RT-PCR experiments failed to detect an increase of *SRSF2* mRNA level in treated cells (Supplementary Figure 10A), the accumulation of SRSF2 protein in response to cisplatin is mainly a post-transcriptional event. In addition, inhibition of SRSF2 expression strongly impaired the occurrence of apoptosis induced by cisplatin (Figure 5A). The use of a distal 5' splice donor site of exon 8 in the human *caspase-8* mRNA leads to the synthesis of an alternative splice variant, *caspase-8L*, a competitive inhibitor of caspase-8 (Himeji *et al*, 2002). In our

cells, cisplatin decreased the *caspase-8L/caspase-8a* ratio (Figure 5B). This effect was prevented when SRSF2 was neutralized, indicating that SRSF2 is involved in *caspase-8* pre-mRNA splicing on cisplatin treatment. Of note, caspase-8 was required for apoptosis in this setting, as co-treating cells with cisplatin and the specific cell-permeable caspase-8 inhibitor IETD-CHO significantly decreased the number of apoptotic cells and prevented the decrease of the *caspase-8L/caspase-8a* ratio (Supplementary Figure 10C and D). Taken together, these results indicate that SRSF2 accumulates on cisplatin treatment and contributes to cisplatin-induced apoptosis. To assess whether acetylation/phosphorylation signalling networks could have a role in this context, we first analysed the acetylated status of SRSF2. Immunoprecipitation experiments demonstrated that SRSF2 acetylation was dramatically lost on cisplatin treatment (Figure 5C). This effect was specific of SRSF2 as cisplatin strongly stimulated the acetylation of the transcription factor E2F1, in agreement with previous data (Ianari *et al*, 2004). Consistent with the loss of SRSF2 acetylation, immunoblotting and quantitative RT-PCR experiments demonstrated that cisplatin induced a significant decrease of both *Tip60* mRNA and protein levels as compared with untreated cells, which correlated with the occurrence of apoptosis as detected by caspase-3 activation (Figure 5D). These results were also confirmed in H358 cells (Supplementary Figure 10B). It was recently shown that the circadian transcription factor Clock controls *Tip60* gene expression in human lung carcinoma cell lines, and that high levels of both Clock and *Tip60* proteins correlate with resistance to cisplatin (Miyamoto *et al*, 2008). Interestingly, we observed that downregulation of *Tip60* mRNA and protein on cisplatin-induced apoptosis was associated with the decrease of Clock protein level (Figure 5D). As cisplatin did not affect *Tip60* mRNA stability as measured after actinomycin D treatment (Supplementary Figure 11), our results suggest that Clock might be involved in the decrease of *Tip60* gene expression following cisplatin exposure. Moreover, while expression of HDAC6 protein did not significantly vary in response to cisplatin, its neutralization strongly prevented the accumulation of SRSF2 (Figure 5E, upper panel), indicating that HDAC6 is involved in SRSF2 increase in that case. These results were confirmed in 3T3 cells (Figure 5E, lower panel). Finally, and concomitant with the loss of SRSF2 acetylation, increased levels of P-SRSF2

Figure 2 Acetylation by *Tip60* controls SRSF2 turnover. (A) H358 and H1299 cell lines were transfected for 72 h with *mismatch* or *Tip60*(2) siRNAs. SRSF2, SRSF1 and *Tip60* protein levels were analysed by western blotting. Actin was used as a loading control (upper panel). SRSF2 mRNA levels were quantified by quantitative RT-PCR. *G3pdh* was used as an internal control (lower panel). (B) H1299 cells were co-transfected for 72 h with *mismatch* or *Tip60*(2) siRNAs in the presence or absence of either wild-type (WT) HA-*Tip60* or mutant (G380) HA-*Tip60*^{G380} with impaired HAT domain. SRSF2 protein expression was assessed by western blotting (upper panel). Neutralization or overexpression of *Tip60* was verified by quantitative RT-PCR (lower panel). (C) HA-tagged SRSF2 protein was co-expressed for 36 h in H1299 cells with either wild-type (WT) HA-*Tip60* or mutant (G380) HA-*Tip60*^{G380}, and treated (+) or not (–) for an additional 18 h with MG132. Western blot analysis using anti-HA antibody is presented (upper panel). SRSF2 and actin signal intensities were quantified using the ImageJ software and the relative densitometric areas for SRSF2–HA were determined according to actin signal in each condition (lower panel). (D) H1299 cells were transfected for 36 h with plasmid encoding either wild-type (WT) HA-*Tip60* or mutant (G380) HA-*Tip60*^{G380} protein and treated (+) or not (–) for an additional 18 h with MG132. SRSF2 protein level was analysed by western blot. (upper panel) The relative densitometric areas for SRSF2 were determined as in C (lower panel). (E) H1299 cells were transfected for 36 h with plasmid encoding lysine 52 mutant (K52R) HA-tagged SRSF2 protein in the presence or absence (–) of either wild-type (WT) HA-*Tip60* or mutant (G380) HA-*Tip60*^{G380} and treated (+) or not (–) for an additional 18 h with MG132 as indicated. SRSF2(K52R) and *Tip60* proteins were detected by western blotting using anti-HA antibody (upper panel) and the relative densitometric areas for SRSF2(K52R) were determined (lower panel). (F) H1299 cells were transfected for 48 h with HA-SRSF2 WT or K52R expression vector then treated with cycloheximide (CHX) for the indicated times. Whole-cellular extracts were subjected to western blotting using anti-HA antibody (upper panel). HA-SRSF2 densitometric signals were normalized to actin. A value of 1 was arbitrarily assigned to the signal obtained at 0 time of CHX treatment (lower panel).

Figure 3 HDAC6 acts as a positive regulator of SRSF2 protein level by counteracting Tip60-mediated effects. (A) H1299 cells were co-transfected for 48 h with HA-tagged SRSF2 and Flag-tagged HDAC6 expression vectors. SRSF2 protein level was analysed by western blotting using an anti-HA antibody. (B) H358 and H810 cells were transfected for 72 h with *mismatch* or *HDAC6* siRNAs. Expression of SRSF2 and SRSF1 proteins was studied by western blotting. (C) H1299 cells were transfected for 72 h with either *mismatch* or *HDAC6* siRNAs. Total cellular extracts were subjected to immunoprecipitation (IP) with anti-Ac-K52 SRSF2 antibody followed by immunoblotting with anti-SRSF2 antibody (upper panel). H1299 cells were transfected for 48 h with HA-tagged SRSF2 WT or K52R expression vector, in the presence (+) or absence (-) of Flag-tagged HDAC6 and subjected to western blot analysis for detection of HA-SRSF2 expression. The relative densitometric areas for HA-SRSF2 were determined according to actin signal (middle panel). H1299 cells were co-transfected for 48 h with HA-tagged SRSF2 WT or K52R expression vector, in the presence (+) or absence (-) of Flag-tagged HDAC6 or HDAC6 expression (lower panel). (D) Whole-cellular extracts derived from 3T3 cell lines wild-type (WT), HDAC6^{-/-} (KO) or HDAC6^{-/-} re-expressing the wild-type HDAC6 (+ WT) were used to analyse SRSF2 protein level (upper panel). One of the HDAC6-deficient clones was used to establish new lines re-expressing wild-type HDAC6 (+ WT) or a catalytically dead (+ HD^m) or a non-ubiquitin-binding mutant of HDAC6 (Ub^m; Boyault *et al*, 2007b). Whole-cellular extracts were used to study SRSF2 expression (lower panel). (E) Same cells were treated (+) or not (-) with proteasome inhibitor MG132 for 18 h and SRSF2 expression was analysed by western blot. (F) HA-tagged SRSF2 WT or K52R protein was co-expressed for 48 h with HA-tagged Tip60 protein in H1299 cells, in the presence of increasing amount of Flag-tagged HDAC6 expression vector. SRSF2 protein expression was detected by western blotting using an anti-HA antibody.

Figure 4 Tip60 downregulates SRSF2 phosphorylation by preventing SRPK1/2 nuclear translocation. (A) H1299 cells were co-transfected for 48 h with HA-tagged SRSF2 and either HA-Tip60 WT or HA-Tip60^{G380} expression vectors and treated for 18 h with MG132. SRSF2 phosphorylation was studied by western blotting using either mAb104 or phosphorylated SRSF2 protein (P-SRSF2) antibody. (B) H1299 cells were transfected for 48 h with plasmid encoding HA-tagged SRSF2 protein in the presence or absence of HA-tagged Tip60 expression vector and treated with MG132 18 h before harvesting. Cellular extracts were subjected to immunoprecipitation (IP) with an anti-HA antibody followed by immunoblotting with an anti-P-SRSF2 or anti-SRSF2 antibody. (C) H358 cells were transfected for 72 h with either *mismatch* or *Tip60(1)* siRNAs. SRSF2 phosphorylation was studied by western blotting using a specific P-SRSF2 antibody (left panel). Neutralization of Tip60 was controlled by quantitative RT-PCR (right panel). (D) HA-tagged SRSF2 protein was co-expressed in H1299 cells with HA-tagged Tip60 protein. Total cellular extracts (upper panel) or cytoplasmic (C) and nuclear (N) extracts (lower panel) were subjected to western blot. Anti- α -tubulin and anti-histone H3 antibodies were used to assess the fractionation efficiency. (E) H810 cells were transfected for 72 h with *mismatch* or *Tip60(1)* siRNAs. Total cellular extracts were immunoblotted with anti-SRPK1 or anti-SRPK2 antibody (upper panel). Cytoplasmic (C) and nuclear (N) extracts were subjected to immunoblotting using the indicated antibodies. (lower panel; F) H810 cells were transfected for 72 h with *mismatch* or *Tip60(2)* siRNA. Immunolocalization of either SRPK1 or SRPK2 protein (green) was visualized by immunofluorescence. DAPI staining (blue) was used to counterstain nuclei.

were detected in response to cisplatin (Figure 5F) and were associated with the nuclear accumulation of both SRPK1 and SRPK2 kinases, as detected using both subcellular fractionation experiments (Figure 5G) and immunofluorescence studies (Supplementary Figure 12). Overall, these results demonstrate that cisplatin induces the accumulation of a hypoacetylated and phosphorylated form of SRSF2, by a

mechanism involving the Tip60, HDAC6, SRPK1 and SRPK2 proteins.

SRPK1 and SRPK2 differentially control SRSF2 phosphorylation and cell fate in response to cisplatin

SRPK1 and SRPK2 kinases have both overlapping and unique functions in mammalian cells (Mathew *et al*, 2008). Finally,

Figure 5 SRSF2 accumulates in a hypoacetylated/phosphorylated form in response to cisplatin treatment and is required for apoptosis. (A, B) H358 cells were transfected for 48 h with either *mismatch* or *SRSF2* siRNAs and treated (+) or not (–) for an additional 24 h with cisplatin (100 μ M). (A) Western blot analysis was performed using anti-SRSF2 or anti-active caspase-3 antibody (left panel). Apoptosis was quantified by flow cytometry analysis of active caspase-3 in untreated (grey bars) or treated (black bars) cells (right panel). (B) RT-PCR analysis using specific primers of *caspase-8* splice variants. *Gapdh* was used as an internal control (left panel). Densitometric signals were quantified using the Image J software and the relative ratio *caspase-8L/caspase-8a* was calculated in either untreated (grey bars) or treated (black bars) cells (right panel). (C) H810 cells were treated or not for 24 h with 100 μ M cisplatin. Nuclear-enriched extracts were prepared and immunoprecipitation (IP) of acetylated proteins was performed using an anti-acetyl-lysine (Ac-K) antibody followed by immunoblotting using either an anti-SRSF2 or anti-E2F1 antibody. (D) H810 cells were treated or not for 24 h with 100 μ M cisplatin and subjected to western blot analysis (left panel). Tip60 transcript level was quantified by quantitative RT-PCR (right panel). (E) H358 cells were transfected for 48 h with *mismatch* or *HDAC6* siRNAs and treated (+) or not (–) for an additional 24 h with 100 μ M cisplatin. Western blot analysis was performed for the detection of SRSF2 or HDAC6 protein (upper panel). Wild-type or HDAC6 knockout 3T3 cells were treated (+) or not (–) with 100 μ M cisplatin for 24 h and SRSF2 protein level was assessed by immunoblotting (lower panel). (F) Total cellular extracts were obtained from H358 and H1299 cells treated or not for 24 h with 100 μ M cisplatin. Phosphorylated SRSF2 protein (P-SRSF2) and SRSF2 protein levels were analysed by western blotting. (G) Cytoplasmic and nuclear extracts from H810 cells treated or not for 24 h with 100 μ M cisplatin were subjected to western blotting.

we investigated the role of each SRPK in cisplatin-induced SRSF2 phosphorylation and apoptosis. For this purpose, H358 (Figure 6) and H1299 (data not shown) cells were transfected with siRNA targeting either *SRPK1* or *SRPK2*, and were

subjected or not to cisplatin exposure for 24 h. We observed that neutralization of *SRPK2* significantly prevented the phosphorylation of SRSF2 (Figure 6A, left panel) and the induction of apoptosis following cisplatin treatment

Figure 6 SRPK2 but not SRPK1 is required for SRSF2 phosphorylation and apoptosis in response to cisplatin. **(A, B)** H358 cells were transfected for 48 h with either *mismatch*, *SRPK1* or *SRPK2* siRNAs and treated (+) or not (–) for an additional 24 h with 100 μ M cisplatin. **(A)** Western blot analyses of the indicated proteins (left panel). Apoptosis was quantified in untreated (grey bars) or treated (black bars) cells by analysis of caspase-3 activation by flow cytometry (right panel). **(B)** RT-PCR analyses of *caspase-8* splice variants. *Gapdh* was used as an internal control (left panel). The relative ratio *caspase-8L/caspase-8a* was calculated in either untreated (grey bars) or treated (black bars) cells after densitometric quantification of the signals (right panel). **(C)** H358 cells were transfected for 48 h with *mismatch* or *SRPK2* siRNAs and treated or not for an additional 24 h with 100 μ M cisplatin. Cell cycle distribution was analysed by flow cytometry. Percentages of cells in the different phases are indicated.

(Figure 6A, left and right panels). Of note, and as shown by western blotting (Figure 6A, left panel), exposure to cisplatin led to the appearance of a cleaved product of SRPK2 that has been previously described in apoptotic cells (Kamachi *et al*, 2002). In addition, and consistent with apoptosis measurements, the knockdown of SRPK2 strongly increased the *caspase-8L/caspase-8a* ratio in cisplatin-treated cells (Figure 6B). Similar results were obtained in H1299 cells (data not shown). Altogether, these results demonstrate that SRPK2 is a critical regulator of SRSF2 during cisplatin-induced apoptosis. By contrast, the neutralization of SRPK1 did not prevent the accumulation of P-SRSF2, and apoptosis sharply increased as detected by western blot (Figure 6A, left panel) or flow cytometry (Figure 6A, right panel). These data indicate that SRPK1 inhibits rather than stimulates cisplatin-induced apoptosis. Therefore, it appears that SRPK1 and SRPK2 kinases do not have the same role in response to cisplatin. Finally, as apoptosis was impaired in SRPK2-depleted cells on drug treatment, we wondered about the fate of these cells. To answer, the cell cycle distribution was analysed by flow cytometry. As depicted in Figure 6C, while appearance of apoptotic cells with a sub-G₁ DNA content was observed after cisplatin exposure, inhibiting SRPK2 expression in these conditions induced a G₂/M arrest. Overall, these data indicate

that SRPK-regulated SRSF2 phosphorylation controls cell fate decision in response to cisplatin treatment.

Discussion

A high-resolution mass spectrometry analysis recently identified 3600 lysine acetylation sites on 1750 proteins (Choudhary *et al*, 2009). Interestingly, when these proteins were classified according to their cellular functions, two classes emerged: the first one bringing together cell cycle regulators and the second one, RNA-splicing components. Moreover, when the architecture of acetylated proteins was analysed, RRM domains were overrepresented in the lysine acetylome, strongly supporting a role of this post-translational modification in the control of pre-mRNA processing events. In this study, we unravel the first acetylation/phosphorylation signalling network regulating the turnover and activity of a key splicing regulator, namely the SR protein SRSF2. In this setting, we identify a closed interplay among SRSF2, the Tip60 acetyltransferase, the HDAC6 deacetylase, and the SRPK1 and SRPK2 kinases. Therefore, besides phosphorylation, we characterize lysine acetylation as a new post-translational modification of SR proteins, whose role as a

regulator of pre-mRNA splicing events has now to be fully considered.

Only a few data exist about the molecular mechanisms regulating SRSF2 protein expression. It is known that, when highly expressed, SRSF2 negatively controls its own expression, through activation of alternative splicing events leading to the generation of distinct splice variants that are targeted by the non-sense-mediated mRNA decay machinery (Sureau *et al*, 2001). In addition, we recently showed that E2F1 is a direct transcriptional factor towards *SRSF2* promoter (Merdzhanova *et al*, 2008). In this study, we demonstrate that Tip60 acetylates SRSF2 on its lysine 52 (K52) residue and promotes its proteasomal degradation, thereby characterizing a novel mechanism that controls SRSF2 protein level. K52 appears to be a critical residue for proteasome targeting, as its substitution by arginine significantly enhances the half-life of a mutant SRSF2(K52R). It has been previously shown that SRSF2 partially co-localizes with proteasomes and accumulates under treatment with the proteasome inhibitor lactacystin (Dino Rockel and von Mikecz, 2002; Baldin *et al*, 2008). SRSF6 is also targeted by the proteasome (Lai *et al*, 2003). Therefore, these and our data suggest that proteasome-dependent proteolysis could be a general mechanism to control turnover of SR proteins. Most of the examples described in the literature designate lysine acetylation as a stabilizing post-translational modification, through a blocking effect which hinders lysine ubiquitination (Sadoul *et al*, 2008). In contrast and consistent with our results, lysine acetylation has also been reported as a signal enhancing protein degradation (Caron *et al*, 2005; Leduc *et al*, 2006; Sadoul *et al*, 2008). We do not elucidate here the molecular mechanisms by which Tip60 targets SRSF2 to proteasomal degradation. Notably, we do not provide evidence that SRSF2 is ubiquitinated on Tip60 overexpression. As previously shown for p53 (Asher *et al*, 2002, 2005), it is possible that SRSF2 is degraded by an ubiquitin-independent proteasomal pathway. However, as Tip60 can interact with some E3-ubiquitin ligases such as MDM2 (Legube *et al*, 2002) or Pirh2 (Logan *et al*, 2004), it is tempting to speculate that Tip60 could act as an adaptor to allow the recruitment and to stimulate the activity of specific ubiquitin ligase complex towards SRSF2. Furthermore, we demonstrate that the deacetylase HDAC6 interacts with and stabilizes SRSF2 by a mechanism requiring both its deacetylase and ubiquitin-binding domains, thereby strongly suggesting a role of ubiquitination in the control of SRSF2 protein turnover. Again, lysine 52 is a critical residue in this process as the mutant SRSF2(K52R) is insensitive to HDAC6 expression. Therefore, these results suggest that deacetylation of SRSF2 by HDAC6 could prevent its further ubiquitination and degradation. Alternatively, as high-affinity binding of HDAC6 to ubiquitin prevents the access of other cellular factors to polyubiquitin chains, and protects ubiquitinated proteins from proteasomal degradation (Boyault *et al*, 2007a), HDAC6 could bind an acetylated and ubiquitinated form of SRSF2 and prevent its further degradation. This could explain why SRSF2 still accumulates in cells overexpressing Tip60 in the presence of high amounts of HDAC6 (Figure 3F) and supports a model in which the equilibrium between Tip60 and HDAC6 activities controls SRSF2 protein turnover (Figure 7A). Further experiments are now needed to more thoroughly examine the relationship between SRSF2 and the components of the ubiquitination machinery.

A In unstressed conditions

B On cisplatin treatment

Figure 7 A model for the roles of Tip60, HDAC6, SRPK1 and SRPK2 proteins in the control of SRSF2 protein in both unstressed (A) and genotoxic stressed (B) conditions. (A) In unstressed cells, Tip60 acetylates SRSF2 on its lysine 52 residue and prevents SRPK1 and SRPK2 nuclear localization. SRSF2 accumulates in a hyperacetylated/hypophosphorylated form that is subjected to proteasomal degradation. This effect is counterbalanced by the HDAC6 deacetylase, which positively controls SRSF2 protein level by deacetylating SRSF2 and preventing its proteasomal degradation. (B) On cisplatin treatment, Tip60 protein level strongly decreases leading to the nuclear accumulation of both SRPK1 and SRPK2 kinases, to the stabilization of SRSF2 in a hypoacetylated/phosphorylated form by a mechanism involving HDAC6. SRSF2 and SRPK2 cooperate to induce apoptosis through regulation of the splicing switch of *caspase-8* pre-mRNA. In contrast, SRPK1 appears to act as an anti-apoptotic factor. In the absence of SRPK2, apoptosis is blocked and treated cells accumulate in G₂/M phase indicating that SRPK-mediated SRSF2 phosphorylation controls cell fate decision.

Phosphorylation of SR proteins is essential for their nuclear import and is required for initiation of spliceosome assembly (Cao *et al*, 1997; Xiao and Manley, 1997). Conversely, dephosphorylation of SR proteins is critical for splicing catalysis once the spliceosome is assembled (Mermoud *et al*, 1992; Cao *et al*, 1997) and for several post-splicing events (Sanford *et al*, 2005). Therefore, phosphorylation of SR proteins must be tightly regulated. Several SR protein kinases have been identified to date. The SRPK1 and SRPK2 kinases are among the best-characterized ones. They are detected in both the cytoplasm and the nucleus (Wang *et al*, 1998; Ding *et al*, 2006) and have an important role in nuclear import as well as in intranuclear localization of SR proteins (Gui *et al*, 1994; Yeakley *et al*, 1999). SRPKs are major kinases for SR proteins in mammalian cells (Hayes *et al*, 2006). Consistently, we provide evidence that both SRPK1 and SRPK2 proteins are the main regulators of SRSF2 phosphorylation in our cellular models. Moreover, we demonstrate that Tip60 decreases the phosphorylation

of SRSF2 by a mechanism requiring its HAT activity, unraveling a close interplay between acetylation and phosphorylation signalling pathways. It has been recently proposed, in the same way that phosphorylation affects acetylation of a neighbouring lysine, that acetylation might also regulate phosphorylation of adjacent or distant residues (Yang and Seto, 2008). In addition recent studies have shown that, although recognition of the RS domain of SRSF1 by a docking groove on SRPK1 is sufficient to initiate processive and directional phosphorylation, continued phosphorylation relies on the fine-tuning of contacts with RRM modules (Hagopian *et al*, 2008; Ngo *et al*, 2008). On the basis of these data, it might be speculated that acetylation of SRSF2 inside its RRM by Tip60 could interfere with SRPK-mediated phosphorylation. However, as HDAC6 as well as the mutation of lysine 52 into a non-acetylatable residue do not modify SRSF2 phosphorylation (V Edmond, unpublished results), acetylation is probably not involved in the inhibition of SRSF2 phosphorylation by Tip60. Consistent with such hypothesis, we provide further evidence that Tip60, but not its inactive catalytic mutant Tip60^{G380}, inhibits the nuclear translocation of both SRPK1 and SRPK2 kinases. These data indicate that an inappropriate subcellular distribution of SRPKs might mainly contribute to the negative effect of Tip60 on SRSF2 phosphorylation. It has been shown that the spacer sequence that splits the conserved kinases domains of SRPK1 and SRPK2 into two blocks is involved in their partitioning between the cytoplasm and the nucleus (Ding *et al*, 2006). Whether Tip60 could directly or indirectly target this accessory domain to affect nuclear accumulation of SRPKs remains to be determined. Of note, SRPK1 was identified as a putative acetylated protein by Choudhary *et al* (2009) thereby suggesting that Tip60 could at least acetylate SRPK1 to control its subcellular distribution. However, as signalling pathways involving the major molecular chaperone HSP90 (Zhong *et al*, 2009) or AKT (Jang *et al*, 2009) were recently found to control SRPK1/2 subcellular partitioning, additional experiments are required to explore the effects of Tip60 on these processes.

In agreement with an important role of SRSF2 during DNA Damage Response (DDR; Merdzhanova *et al*, 2008), we finally demonstrate that SRSF2 is upregulated and required for cellular apoptosis in response to cisplatin treatment. Importantly, we show that, in this context, SRSF2 accumulates in a phosphorylated/hypoacetylated form. Such post-translational modifications of SRSF2 are accompanied by a strong decrease of Tip60 mRNA and protein expression, as well as with the nuclear accumulation of both SRPK1 and SRPK2 kinases. The crucial role of Tip60 during DDR is now emerging (Squatrito *et al*, 2006) and high amounts of Tip60 protein have been correlated with cisplatin resistance in several human lung carcinoma cell lines (Miyamoto *et al*, 2008). Therefore, our results are consistent with a model in which cisplatin-induced apoptosis involves Tip60 down-regulation, SRSF2 stabilization and SRSF2 phosphorylation (Figure 7B). In addition, as HDAC6 is required for SRSF2 stabilization (Figure 5E) as well as for apoptosis occurrence (data not shown) in this context, the Tip60/HDAC6 ratio would have a key role in the control of SRSF2 expression in response to cisplatin. Moreover, we also demonstrate that SRPK2 is absolutely required for SRSF2 phosphorylation and cisplatin-induced apoptosis. In contrast, SRPK1 appears

to have opposite functions as its neutralization increases rather than inhibits apoptosis. Of note, such a role of SRPK1 in resistance to cisplatin has been previously reported in pancreatic carcinoma (Hayes *et al*, 2006, 2007). Therefore, and as recently suggested (Mathew *et al*, 2008), our data provide further evidence that each SRPK has both overlapping and independent functions. Furthermore, they support a critical role of SRPK2-mediated SRSF2 phosphorylation in the induction of apoptosis following cisplatin treatment.

To conclude, our study highlights a new acetylation/phosphorylation signalling network targeting the SRSF2 protein, to control cellular apoptosis in response to genotoxic stress. These data reinforce the connection between chromatin and splicing players, and open the way to further experiments aiming at thoroughly examining the role of such connection in the control of pre-mRNA splicing events.

Materials and methods

Cell lines, cell treatments, plasmids and transfection

H358, H1299, H810, H69 human lung carcinoma cell lines and SAOS2 osteosarcoma cells were cultured as described (Salon *et al*, 2007; Merdzhanova *et al*, 2008). Stable inducible SRSF2 clones derived from H358 cells were obtained using a modified tetracyclin-regulated inducible expression system (Tet-On System, Clontech, Ozyme, Saint Quentin en Yvelines, France) as previously described (Salon *et al*, 2006). The parental and HDAC6^{-/-} 3T3 cell lines, as well as the 3T3 cell lines derived from HDAC6-deficient cells re-expressing wild-type HDAC6 (+ WT) or HDAC6 bearing mutations either in the two catalytic deacetylase domains (HDtm) or in the ZnF-UBP ubiquitin-binding domain (Ubtm) have been previously described (Boyault *et al*, 2007b). They were maintained in DMEM (GibcoBRL) supplemented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin in 5% CO₂ at 37°C. Plasmids and reagents used in this study are described in detail in the Supplementary data.

Immunoprecipitation and western blotting experiments

Immunoprecipitation and western blotting experiments were performed as previously described (Salon *et al*, 2006). All the antibodies used in this study are described in the Supplementary data. Cellular fractionation experiments were performed as described in the Supplementary data.

In vitro acetylation assays

Distinct cDNA encoding truncated forms of SRSF2 protein were fusionned in frame with GST by subcloning into pGEX-6P3 plasmid. Beads coated with GST, GST-SRSF2(1–60), GST-SRSF2(60–115), GST-SRSF2(115–221) or GST-SRSF1 fusion proteins were prepared according to the manufacturer's protocol (Bulk GST Purification module, Pharmacia Biotech). 'In vitro' acetyltransferase assays were performed using 2 µg of each recombinant GST-SRSF2 fusion peptides, 1 µg of recombinant His-tagged Tip60^{212–513} or His-tagged GCN5 protein and 0.05 µCi of [¹⁴C]acetyl-CoA, as described previously (Leduc *et al*, 2006).

Transfection of siRNA oligonucleotides

The sequences designed to specifically target human SRSF2, Tip60, HDAC6, *srpk1* and *srpk2* RNAs are listed in the Supplementary data. Cells were transfected with siRNA oligonucleotides duplex using Oligofectamine reagent according to the manufacturer's instructions (Invitrogen, Cergy Pontoise, France), excepted for H810 cells transfected with Hi-Perfect reagent (Qiagen). The cells were analysed 72 h after transfection.

Quantitative RT-PCR and RT-PCR analyses

Quantitative RT-PCR was performed on Stratagene MX3005P apparatus (Agilent Technologies), as previously described (Van Den Broeck *et al*, 2008). The specific primers used for mRNA amplification are described in the Supplementary data. RT-PCR

analysis of caspase-8 splice variants was performed as described previously (Merdzhanova *et al*, 2008).

Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

Acknowledgements

We thank Patricia Betton, Pascal Perron and Celine Barrial-Lampreia for technical assistance. This work was supported by the Ligue

Nationale contre le Cancer (Equipe Labellisée Ligue, 2007) and by the Conseil Scientifique National d'AGIR *à dom*. This work was supported by the Comité Départemental Isère de la Ligue Nationale contre le Cancer. Valerie Edmond was supported by a grant from the Conseil Scientifique National d'AGIR *à dom*. SK laboratory is supported by ANR, ARC, INCa.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Asher G, Lotem J, Sachs L, Kahana C, Shaul Y (2002) Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. *Proc Natl Acad Sci USA* **99**: 13125–13130
- Asher G, Tsvetkov P, Kahana C, Shaul Y (2005) A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. *Genes & Dev* **19**: 316–321
- Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, Coux O (2008) A novel role for PA28γ-proteasome in nuclear speckle organization and SR protein trafficking. *Mol Biol Cell* **19**: 1706–1716
- Batsche E, Yaniv M, Muchardt C (2006) The human SWI/SNF subunit Brm is a regulator of alternative splicing. *Nat Struct Mol Biol* **13**: 22–29
- Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, Matthias P, Muller CW, Khochbin S (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. *EMBO J* **25**: 3357–3366
- Boyault C, Sadoul K, Pabion M, Khochbin S (2007a) HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. *Oncogene* **26**: 5468–5476
- Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, Khochbin S (2007b) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. *Genes Dev* **21**: 2172–2181
- Cao W, Jamison SF, Garcia-Blanco MA (1997) Both phosphorylation and dephosphorylation of ASF/SF2 are required for pre-mRNA splicing *in vitro*. *RNA* **3**: 1456–1467
- Caron C, Boyault C, Khochbin S (2005) Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. *Bioessays* **27**: 408–415
- Choudhary C, Kumar C, Gnäd F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science* **325**: 834–840
- Ding JH, Zhong XY, Hagopian JC, Cruz MM, Ghosh G, Feramisco J, Adams JA, Fu XD (2006) Regulated cellular partitioning of SR protein-specific kinases in mammalian cells. *Mol Biol Cell* **17**: 876–885
- Dino Rockel T, von Mikecz A (2002) Proteasome-dependent processing of nuclear proteins is correlated with their subnuclear localization. *J Struct Biol* **140**: 189–199
- Gui JF, Lane WS, Fu XD (1994) A serine kinase regulates intracellular localization of splicing factors in the cell cycle. *Nature* **369**: 678–682
- Hagopian JC, Ma CT, Meade BR, Albuquerque CP, Ngo JC, Ghosh G, Jennings PA, Fu XD, Adams JA (2008) Adaptable molecular interactions guide phosphorylation of the SR protein ASF/SF2 by SRPK1. *J Mol Biol* **382**: 894–909
- Hayes GM, Carrigan PE, Beck AM, Miller LJ (2006) Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. *Cancer Res* **66**: 3819–3827
- Hayes GM, Carrigan PE, Miller LJ (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. *Cancer Res* **67**: 2072–2080
- Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T, Harada M (2002) Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. *Blood* **99**: 4070–4078
- Ianari A, Gallo R, Palma M, Alesse E, Gulino A (2004) Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. *J Biol Chem* **279**: 30830–30835
- Jang SW, Liu X, Fu H, Rees H, Yepes M, Levey A, Ye K (2009) Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. *J Biol Chem* **284**: 24512–24525
- Kamachi M, Le TM, Kim SJ, Geiger ME, Anderson P, Utz PJ (2002) Human autoimmune sera as molecular probes for the identification of an autoantigen kinase signaling pathway. *J Exp Med* **196**: 1213–1225
- Lai MC, Lin RI, Tarn WY (2003) Differential effects of hyperphosphorylation on splicing factor Srp55. *Biochem J* **371**: 937–945
- Leduc C, Claverie P, Eymin B, Col E, Khochbin S, Brambilla E, Gazzeri S (2006) p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation. *Oncogene* **25**: 4147–4154
- Legube G, Linares LK, Lemercier C, Scheffner M, Khochbin S, Trouche D (2002) Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. *EMBO J* **21**: 1704–1712
- Liu HX, Zhang M, Krainer AR (1998) Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. *Genes Dev* **12**: 1998–2012
- Logan IR, Sapountzi V, Gaughan L, Neal DE, Robson CN (2004) Control of human PIRH2 protein stability: involvement of TIP60 and the proteasome. *J Biol Chem* **279**: 11696–11704
- Long JC, Caceres JF (2009) The SR protein family of splicing factors: master regulators of gene expression. *Biochem J* **417**: 15–27
- Loomis RJ, Naoe Y, Parker JB, Savic V, Bozovsky MR, Macfarlan T, Manley JL, Chakravarti D (2009) Chromatin binding of SRp20 and ASF/SF2 and dissociation from mitotic chromosomes is modulated by histone H3 serine 10 phosphorylation. *Mol Cell* **33**: 450–461
- Mathew R, Hartmuth K, Mohlmann S, Urlaub H, Ficner R, Luhrmann R (2008) Phosphorylation of human PRP28 by SRPK2 is required for integration of the U4/U6-U5 tri-snRNP into the spliceosome. *Nat Struct Mol Biol* **15**: 435–443
- Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2008) E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SRSF2. *Cell Death Differ* **15**: 1815–1823
- Mermoud JE, Cohen P, Lamond AI (1992) Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing. *Nucleic Acids Res* **20**: 5263–5269
- Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, Kidani A, Tawara A, Kohno K (2008) Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. *J Biol Chem* **283**: 18218–18226
- Ngo JC, Giang K, Chakrabarti S, Ma CT, Huynh N, Hagopian JC, Dorrestein PC, Fu XD, Adams JA, Ghosh G (2008) A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. *Mol Cell* **29**: 563–576
- Sadoul K, Boyault C, Pabion M, Khochbin S (2008) Regulation of protein turnover by acetyltransferases and deacetylases. *Biochimie* **90**: 306–312
- Salon C, Eymin B, Mischeau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S (2006) E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). *Cell Death Differ* **13**: 260–272

- Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2007) E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. *Oncogene* **26**: 6927–6936
- Sanford JR, Ellis J, Caceres JF (2005) Multiple roles of arginine/serine-rich splicing factors in RNA processing. *Biochem Soc Trans* **33**: 443–446
- Schwartz S, Meshorer E, Ast G (2009) Chromatin organization marks exon-intron structure. *Nat Struct Mol Biol* **16**: 990–995
- Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, Khochbin S (2001) Identification of components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination signaling pathways. *Mol Cell Biol* **21**: 8035–8044
- Sims III RJ, Millhouse S, Chen CF, Lewis BA, Erdjument-Bromage H, Tempst P, Manley JL, Reinberg D (2007) Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. *Mol Cell* **28**: 665–676
- Squatrito M, Gorrini C, Amati B (2006) Tip60 in DNA damage response and growth control: many tricks in one HAT. *Trends Cell Biol* **16**: 433–442
- Stamm S (2008) Regulation of alternative splicing by reversible protein phosphorylation. *J Biol Chem* **283**: 1223–1227
- Sureau A, Gattoni R, Dooghe Y, Stevenin J, Soret J (2001) SRSF2 autoregulates its expression by promoting splicing events that destabilize its mRNAs. *EMBO J* **20**: 1785–1796
- Tilgner H, Nikolaou C, Althammer S, Sammeth M, Beato M, Valcarcel J, Guigo R (2009) Nucleosome positioning as a determinant of exon recognition. *Nat Struct Mol Biol* **16**: 996–1001
- Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. *Clin Cancer Res* **14**: 7237–7245
- Wang ET, Sandberg R, Luo S, Khrebtkova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB (2008) Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**: 470–476
- Wang HY, Lin W, Dyck JA, Yeakley JM, Songyang Z, Cantley LC, Fu XD (1998) SRPK2: a differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of pre-mRNA splicing factors in mammalian cells. *J Cell Biol* **140**: 737–750
- Wu JY, Maniatis T (1993) Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. *Cell* **75**: 1061–1070
- Xiao SH, Manley JL (1997) Phosphorylation of the ASF/SF2 RS domain affects both protein-protein and protein-RNA interactions and is necessary for splicing. *Genes Dev* **11**: 334–344
- Yang XJ, Seto E (2008) Lysine acetylation: codified crosstalk with other posttranslational modifications. *Mol Cell* **31**: 449–461
- Yeakley JM, Tronchere H, Olesen J, Dyck JA, Wang HY, Fu XD (1999) Phosphorylation regulates *in vivo* interaction and molecular targeting of serine/arginine-rich pre-mRNA splicing factors. *J Cell Biol* **145**: 447–455
- Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD (2009) Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. *Genes Dev* **23**: 482–495